Sam Brusco, Associate Editor11.07.23
HeartBeam has won a new patent for its novel credit card-size, portable 3D-vector electrocardiogram (VECG) from the U.S. Patent and Trademark Office (USPTO).
The “Electrocardiogram Patch Devices and Methods” (Patent number 11,793,444) describes methods and systems for acute myocardial infarction (AMI or heart attack) detection and/or diagnosis through handheld and adhesive devices. This patent is the third in the U.S. for HeartBeam’s on-demand, 12-lead (12L) wearable cardiac monitor.
The 12L patch is made of a small, continuous, single-lead ECG that can be switched to 12-lead in order to record symptoms as they occur, according to the company. HeartBeam believes the 12L patch can record higher resolution signals and spot conditions that single-lead devices can’t—including ischemia and heart attacks.
“This patent represents an integral part of the company’s strategy to ensure HeartBeam’s disruptive technology is well protected,” HeartBeam founder and CEO Branislav Vajdic, Ph.D told the press. “We believe our 12-lead ECG technology has the potential to become the standard of care and are actively pursuing options to bring the 12-lead extended wear patch to market.”
The company currently holds 11 U.S. patents, four international patents, and 18 pending patent applications. They cover core HeartBeam VECG technological inventions, the company’s AIMIGo system, LIVMOR continuous monitors, extended wear patches, and watch-based 12-lead ECGs.
The “Electrocardiogram Patch Devices and Methods” (Patent number 11,793,444) describes methods and systems for acute myocardial infarction (AMI or heart attack) detection and/or diagnosis through handheld and adhesive devices. This patent is the third in the U.S. for HeartBeam’s on-demand, 12-lead (12L) wearable cardiac monitor.
The 12L patch is made of a small, continuous, single-lead ECG that can be switched to 12-lead in order to record symptoms as they occur, according to the company. HeartBeam believes the 12L patch can record higher resolution signals and spot conditions that single-lead devices can’t—including ischemia and heart attacks.
“This patent represents an integral part of the company’s strategy to ensure HeartBeam’s disruptive technology is well protected,” HeartBeam founder and CEO Branislav Vajdic, Ph.D told the press. “We believe our 12-lead ECG technology has the potential to become the standard of care and are actively pursuing options to bring the 12-lead extended wear patch to market.”
The company currently holds 11 U.S. patents, four international patents, and 18 pending patent applications. They cover core HeartBeam VECG technological inventions, the company’s AIMIGo system, LIVMOR continuous monitors, extended wear patches, and watch-based 12-lead ECGs.